10.5 DEVELOPMENTAL FUNDS Developmental Funds are critical to the future progress of the OSUCCC. During the prior funding period, the OSUCCC benefited from $1,858,197 in CCSG developmental funds. For the $1,308,482 of CCSG dollars used for faculty recruitment, the return to date in total direct costs for CCSG-approved peer-reviewed extramural funding is $ 28,576,879 (22:1 return on investment), and in total funding was $72,421,123 (55:1 return on investment, Table 1). In addition, we used CCSG funds for establishment of two shared resources, the Microarray Shared Resource and the Real Time PCR Shared Resource. A brief summary of the progress with these two facilities is described below, because their operation as fully established shared resources is described elsewhere in this application. In the 1999 CCSG competing renewal, """"""""Developmental Funds"""""""" received a merit descriptor of """"""""excellent"""""""". It was noted that there was no letter of assurance from the University attesting to the statement that developmental funds would be matched on a 10:1 basis, nor was there a clear outline of just how or in what form the University funds would be provided in supplementing the developmental funds. There were additional concerns that the junior to mid-level positions to be recruited during the last two years of the grant period were inadequate in description. Finally, there were concerns that the recruitment of a research mammographer might not be possible without a more research-oriented climate in radiology. In the present application, we provide evidence that the University is now providing the new OSUCCC Director with over $9 M/year in funds, an increase of over $8.5 M/year since our last competitive renewal. These dollars are to be used entirely to continue to develop the cancer program at OSU and as such, are matching to any CCSG dollars provided for this purpose. Written assurance of this $9 M/year commitment from both the OSU President and the Senior Vice President for Health Sciences is provided in section 6.7 of Essential Characteristics. In the present application we have tried to provide a more complete description of all 11 faculty we intend to recruit with CCSG developmental funds. In response to the concerns of first establishing a research environment in imaging prior recruiting a research mammographer, we first invested in recruiting a world-class imaging researcher who has initiated the development of a palpable research program in radiology, now making it more suitable to pursue additional imaging investigators. We are requesting support for continued faculty recruitment and continued shared resource development. We propose to focus our recruitment on 11 new faculty: two in the area of cancer prevention and control, three in basic or translational aspects on solid tumor oncology (breast, gastrointestinal, and prostate), one faculty member for each of biostatistics, pathology and human imaging research and three basic researchers in human cancer genetics. We request CCSG funds to develop three new shared resources (SR): a small animal imaging SR, a pharmacoanalytical SR and a cancer biomedical informatics SR. Both our Internal and External Scientific Advisors believe that strategically directed recruitment and SR development are the two best ways to continue to use new developmental funds, given the success with these funds to date and the resultant growth of the OSUCCC over the past 4 years. In Section 10.5.2, we describe our request for developmental funds for the next funding period. Section 10.5.3 describes the resources available to the OSUCCC to supplement the requested `$1 M annually in developmental funds. Our request represents less than 25% of our total annual direct CCSG request.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-32
Application #
7630211
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-12-01
Budget End
2007-11-30
Support Year
32
Fiscal Year
2007
Total Cost
$870,774
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Farquhar, Neil; Thornton, Sophie; Coupland, Sarah E et al. (2018) Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. J Pathol Clin Res 4:26-38

Showing the most recent 10 out of 2602 publications